Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Today's ATE Announcement was a Zero News Event
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(450)
•••
Comment by davgroon Sep 28, 2023 3:34pm
126 Views
Post# 35660160

RE:Today's ATE Announcement was a Zero News Event

RE:Today's ATE Announcement was a Zero News EventSecond attempt at posting ATE's 5-year technical chart.  Fingers crossed....

[url=https://www.stockwatch.com/Chart/Hist?symbol=ATE®ion=C&d1=20180929&d2=20230928&per=d&npdivs=20&width=830&priceheight=400&ptype=bar&indheight=100&log=F&dplus=0&ind1=vol&ind2=none&ind3=none&ind1p1=12&ind1p2=25&ind1p3=50&ind2p1=12&ind2p2=25&ind2p3=50&ind3p1=12&ind3p2=25&ind3p3=50&pov1=mas&pov2=mas&pov3=none&pov1p1=30&pov1p2=&pov2p1=90&pov2p2=&pov3p1=&pov3p2=&newsInd=T][/url]
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities